229 related articles for article (PubMed ID: 34716035)
21. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of 'Italian Peritoneal Surface Malignancies Oncoteam-S.I.C.O.'.
Marano L; Marrelli D; Sammartino P; Biacchi D; Graziosi L; Marino E; Coccolini F; Fugazzola P; Valle M; Federici O; Baratti D; Deraco M; Di Giorgio A; Macrì A; Pasqual EM; Framarini M; Vaira M; Roviello F;
Ann Surg Oncol; 2021 Dec; 28(13):9060-9070. PubMed ID: 34057569
[TBL] [Abstract][Full Text] [Related]
23. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases.
Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O
Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886
[TBL] [Abstract][Full Text] [Related]
24. Impact of myometrium invasion on survival outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).
Mangieri CW; Valenzuela CD; Solsky IB; Erali RA; Votanopoulos KI; Shen P; Levine EA
J Surg Oncol; 2023 Mar; 127(3):450-456. PubMed ID: 36285743
[TBL] [Abstract][Full Text] [Related]
25. Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Baratti D; Pennacchioli E; Kusamura S; Fiore M; Balestra MR; Colombo C; Mingrone E; Gronchi A; Deraco M
Ann Surg Oncol; 2010 Dec; 17(12):3220-8. PubMed ID: 20585874
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
27. Neighborhood-Level Socioeconomic Disadvantage Predicts Outcomes in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignancy.
Winicki NM; Radomski SN; Florissi IS; Cloyd JM; Gutta G; Grotz TE; Scally CP; Fournier KF; Dineen SP; Powers BD; Veerapong J; Baumgartner JM; Clarke CN; Kothari AN; Maduekwe UN; Patel SH; Wilson GC; Schwartz P; Varley PR; Raoof M; Lee B; Malik I; Johnston FM; Greer JB
Ann Surg Oncol; 2023 Nov; 30(12):7840-7847. PubMed ID: 37620532
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
[TBL] [Abstract][Full Text] [Related]
29. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study.
Feng F; Gao Q; Wu Y; Liu C; Yu Y; Li B; Chu K; Yi B; Cheng Q; Jiang X
Eur J Surg Oncol; 2021 Sep; 47(9):2363-2368. PubMed ID: 34119376
[TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
[TBL] [Abstract][Full Text] [Related]
31. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
[TBL] [Abstract][Full Text] [Related]
32. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.
Rau B; Lang H; Koenigsrainer A; Gockel I; Rau HG; Seeliger H; Lerchenmueller C; Reim D; Wahba R; Angele M; Heeg S; Keck T; Weimann A; Topp S; Piso P; Brandl A; Schuele S; Jo P; Pratschke J; Wegel S; Rehders A; Moosmann N; Gaedcke J; Heinemann V; Trips E; Loeffler M; Schlag PM; Thuss-Patience P
J Clin Oncol; 2024 Jan; 42(2):146-156. PubMed ID: 37906724
[TBL] [Abstract][Full Text] [Related]
33. The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin.
Solomon D; Leigh N; Bekhor E; Feferman Y; Dhorajiya P; Feingold D; Hofstedt M; Aycart SN; Golas BJ; Sarpel U; Labow DM; Magge DR
Surgeon; 2021 Dec; 19(6):e379-e385. PubMed ID: 33423919
[TBL] [Abstract][Full Text] [Related]
34. Surgical and oncological outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a nonacademic center: 25-year experience.
Nikiforchin A; Gushchin V; King MC; Baron E; Nieroda C; Sittig M; Sardi A
J Surg Oncol; 2021 Mar; 123(4):1030-1044. PubMed ID: 33524164
[TBL] [Abstract][Full Text] [Related]
35. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis.
Zhang C; Patel A; Hegeholz D; Brown K; Shostrom V; Pottebaum M; Foster JM
Ann Surg Oncol; 2022 May; 29(5):3337-3346. PubMed ID: 35211861
[TBL] [Abstract][Full Text] [Related]
37. Conditional Survival Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies: An Analysis from the US HIPEC Collaborative.
Beal EW; Srinivas S; Shen C; Kim A; Johnston FM; Greer J; Abbott DE; Pokrzywa C; Raoof M; Grotz TE; Leiting JL; Fournier K; Dineen S; Powers B; Veerapong J; Kothari A; Maduekew U; Maithel S; Wilson GC; Patel SH; Lambert L; Abdel-Misih S; Cloyd JM
Ann Surg Oncol; 2023 Mar; 30(3):1840-1849. PubMed ID: 36310315
[TBL] [Abstract][Full Text] [Related]
38. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
39. Closed hyperthermic intraperitoneal chemotherapy with CO
Diaz E; Fabra I; Vicente E; Quijano Y; Duran H; Malave L; Ruiz P; Costantini G; Nola V; Caruso R; Ferri V
Surg Oncol; 2023 Feb; 46():101901. PubMed ID: 36638761
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
